On this week's episode of Biotech Banter, senior biotech specialist Brian Orelli and health-care analyst David Williamson discuss the tweet of the week from David Miller of AlpineBioVentures, who says, "Tip for those new to the ASCO thing: Abstracts are less than half the story. Posters & presentations are the real data."
We got a lot of data in the abstracts that were released earlier this month. But as David points, out there's more data to come.
The late-0breaking abstracts won't be released until the meeting begins on Friday. There investors can expect to see phase 2 data on AstraZeneca's (NYSE:AZN) ovarian cancer drug olaparib, phase 3 lung cancer data for Eli Lilly's (NYSE:LLY) Cyramza, and phase 3 data for Johnson & Johnson (NYSE:JNJ) and Pharmacyclics' Imbruvica in elderly patients with CLL. There will also be a couple of high-profile melanoma studies: Bristol-Myers Squibb's (NYSE:BMY) Yervoy as an adjuvant therapy after surgery and the use of Merck's (NYSE:MRK) MK-3475 in patients who haven't received Yervoy.
Investors can also look forward to expanded data from the abstracts that were released last week. Brian highlights safety data for Bristol-Myers Squibb's Yervoy-PD1 combo that he's looking forward to seeing. Watch the following video for further insight on what to expect at ASCO.
Brian Orelli has no position in any stocks mentioned. David Williamson owns shares of Johnson & Johnson and Merck. The Motley Fool recommends BMW, Johnson & Johnson, and Nike and owns shares of Johnson & Johnson and Nike. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.